Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7624612 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL854090 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL1773132 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL7612611 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL7563162 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL11806608 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL2404356 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL2162933 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL17027772 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL3310359 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 412 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117779469-A | Construction method of host and guest of photodynamic/quaternary ammonium salt/boric acid antibacterial composite PET fiber coating | 浙江豪欣纺织有限公司 | 2024-03-29 | — | — | CN | claimed |
| CN-106398080-A | Aminated cross-linked segmented copolymer/graphene composite material and preparation method thereof | 北京化工大学 | 2017-02-15 | — | — | CN | claimed |
| JP-10237096-A | — | — | None | — | — | JP | disclosed |
| CN-120682625-B | Wear-resistant flame-retardant cable and preparation method thereof | 西部电缆陕西有限公司 | 2026-02-06 | — | — | CN | disclosed |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| CN-120682625-A | Wear-resistant flame-retardant cable and preparation method thereof | 西部电缆陕西有限公司 | 2025-09-23 | — | — | CN | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| CN-119816491-A | New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2025-04-11 | — | — | CN | disclosed |
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | FUSO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2024-08-29 | — | — | US | disclosed |
| WO-2024140595-A1 | TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 珂阑(上海)医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| CN-118255685-A | Tricyclic compound, pharmaceutical composition and application thereof | 珂阑(上海)医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-0061800-A1 | Anti SRS-A carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them | FISONS plc (GB) | 1982-10-06 | — | — | EP | disclosed |
| EP-0049981-A1 | Valienamine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1982-04-21 | — | — | EP | disclosed |
| US-4324796-A | HYPOGLYCEMIC AGENTS, HYPOKETONEMIC AGENTS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1982-04-13 | — | — | US | disclosed |
| EP-0044940-A1 | Amino-desoxy-1.4;3.6-dianhydro-hexite nitrates, processes for their preparation and pharmaceutical compositions | Dr. Willmar Schwabe GmbH & Co. (DE) | 1982-02-03 | — | — | EP | disclosed |
| US-4265891-A | PROSTAGLANDINS, BRONCHODILATORS, PLATELET AGGREGATION INHIBITORS | GLAXO GROUP LIMITED (GB) | 1981-05-05 | — | — | US | disclosed |
| US-4262128-A | HAVING PROSTAGLANDIN-LIKE BIOLOGICAL PROPERTIES | BURROUGHS WELLCOME CO. (US) | 1981-04-14 | — | — | US | disclosed |
| EP-0025192-A2 | Substituted oxirane carboxylic acids, process for their preparation, their use and medicines containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1981-03-18 | — | — | EP | disclosed |
| US-4204068-A | Nitrogen heterocycles | BURROUGHS WELLCOME CO. (US) | 1980-05-20 | — | — | US | disclosed |
| US-4153606-A | Process for the production of thiazoline-(3) compounds | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | TDP1 2093/4885SIGMAR1 426/4885MAOA 3647/4885 |
| US-20240287019-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1G, CACNA1I, CACNA1H | TDP1 3610/4885SIGMAR1 2729/4885MAOA 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.